BELIZE CITY, Belize, Aug. 24, 2016 /PRNewswire/ — The directors and management of N1 Technologies, Inc. (OTC PINK: NTCHF) announced today that the company has filed a new Biotech Patent with the USPTO for its VIRITRON VPN Bacteriophage Treatment for Pneumonia. The company is a leader in Nanotechnology research, and now has focused on entering the Biotechnology arena with its latest discovery. The VIRITRON VDX and new VIRITRON VPN biopharmaceutical is a Genetically Modified Bacteriophage that is highly effective in fighting antibiotic resistant pneumonia infections. A Bacteriophage is a natural organism that has been proven in various human trials to be highly effective at fighting various infectious bacteria. N1 Technologies intends to develop a treatment for Staph and pneumonia infections based on this unique modified organism technology. The company is working to develop a treatment for a number of antibiotic resistant strains of bacterial infections. “Entering this $30 Billion dollar market is a big step for our company and we are very excited to be moving directly into this arena. We are focused on the financial prospects for our investors and the company,” says CEO Steve Lovern. The company will hire “Wet Labs” leading Geneticists and Bio Engineers to assist in this effort. Once fully developed the company will seek out partners in the pharmaceutical industry to partner with for the manufacturing and marketing of the treatment. Learn more: http://www.N1Technologies.com.
Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words “will” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Corporation’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. Various assumptions or factors are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking information. Those assumptions and factors are based on information currently available to the Corporation. The forward-looking information contained in this release is made as of the date hereof and the Corporation is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained here.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/n1-technologies-patents-viritron-vpn-pneumonia-treatment-300317073.html
SOURCE N1 Technologies, Inc.